CORDIS proporciona enlaces a los documentos públicos y las publicaciones de los proyectos de los programas marco HORIZONTE.
Los enlaces a los documentos y las publicaciones de los proyectos del Séptimo Programa Marco, así como los enlaces a algunos tipos de resultados específicos, como conjuntos de datos y «software», se obtienen dinámicamente de OpenAIRE .
Resultado final
Generate VLPs for two TBV candidates and assess immunogenicity and TB activity
6.4 Preclinical studies completed for adjuvant (se abrirá en una nueva ventana)Preclinical studies completed for adjuvant
7.5 Report on safety and immunogenicity of vectored prime-target immunisation in healthy volunteers (se abrirá en una nueva ventana)Report on safety and immunogenicity of vectored prime-target immunisation in healthy volunteers
1.5 Generation of 8 transgenic P berghei parasites expressing novel P falciparum antigens (se abrirá en una nueva ventana)Creation of 8 transgenic P. berghei parasites expressing novel P. falciparum sporozoite antigens
10.2 Establish relevant committees including PSC, PMMC, ISAC (se abrirá en una nueva ventana)Report on the establishment of relevant committees including the Project Steering Committee and a Project Management and Monitoring Committee, and ISAC
2.1 Liver-stage antigens identified from HLA molecules of parasitized hepatocytes (se abrirá en una nueva ventana)Report on the nature of liver-stage antigens identified by sequencing of eluted peptides from the HLA molecules of parasitized hepatocytes
5.2 Adequate process for lead novel VLPs for initial GMP production (se abrirá en una nueva ventana)Adequate process for lead novel VLPs for initial (Phase I trial scale) GMP production
2.3 Rank ordering of the protective efficacy of new liver-stage antigen candidates (se abrirá en una nueva ventana)Rank ordering of the protective efficacy of new liverstage antigen candidates assessed in in vivo murine models using transgenic parasite challenge
5.1 generation of five new VLPs with SnoopCatcher and SpyCatcher (se abrirá en una nueva ventana)Report on generation of five new VLPs with SnoopCatcher and SpyCatcher and on the relative robustness of each platform for displaying multiple antigens
1.4 Generation of 8 new vectored vaccine candidates (se abrirá en una nueva ventana)Generation of 8 new vectored vaccine candidates expressing the 8 elected antigens of deliverable 1.1.
1.3 Generation of lead bivalent sporozoite VLP suitable for progression to GMP (se abrirá en una nueva ventana)Generation of lead bivalent sporozoite VLP suitable for progression to GMP biomanufacture
4.1 Identification of new novel candidates from natural blockers and proteomic screen (se abrirá en una nueva ventana)Identification of new novel candidates from natural blockers and proteomic screen
4.5 Assess immunogenicity and TBA of bivalent VLPs to select candidate for GMP manufacture (se abrirá en una nueva ventana)Assess immunogenicity and TBA of bivalent VLPs to select candidate for GMP manufacture
3.4 Efficacy of new candidate blood-stage antigens (se abrirá en una nueva ventana)Report on efficacy of new candidate bloodstage antigens
3.1 Preferred VLP for generation of bi-valent blood-stage immunogen (se abrirá en una nueva ventana)Report on preferred VLP for generation of a bi-valent blood-stage immunogen
3.2 Immunogenicity and growth inhibitory activity of the lead blood-stage bivalent VLP (se abrirá en una nueva ventana)Report on the immunogenicity and growth inhibitory activity of the lead blood-stage bivalent VLP
5.3 Comparison of immunogenicity of lead VLPs and evidence of non-interference (se abrirá en una nueva ventana)Comparison of immunogenicity of the VLPs generated with identification of the lead VLPs and evidence of non-interference between lead sporozoite-, blood-stage and transmission-stage VLPs
7.7 Report on safety and immunogenicity of R21b in matrix M adjuvant (se abrirá en una nueva ventana)Report on safety and immunogenicity of R21b in matrix M adjuvant
2.4 Utility of new prime-target immunisation approaches in liver-stage protective immunity in mice (se abrirá en una nueva ventana)Report of the utility of new primetarget immunisation approaches in generating durable liverstage protective immunity in mice
1.6 Efficacy data on new antigens allowing rank ordering (se abrirá en una nueva ventana)Efficacy data on new sporozoite antigens allowing rank ordering of protective efficacy of lead antigens
8.4 Report on safety and immunogenicity of blood-stage VLP/vaccine (se abrirá en una nueva ventana)Report on safety and immunogenicity of bloodstage VLPvaccine in clinical trial
10.8 List of publications (se abrirá en una nueva ventana)List of publications arising from project including any at manuscript preparation stage as some data may not be published until after the end date of the project
4.2 Validation of selected novel candidate and comparison with leading antigens (se abrirá en una nueva ventana)Validation of selected novel candidate and comparison with leading antigens
7.6 Report on efficacy against sporozoite challenge of prime-target immunisation in healthy volunteers (se abrirá en una nueva ventana)Report on efficacy against sporozoite challenge of prime-target immunisation in healthy volunteers
3.3 Structural studies of PfRH5 pathway components (se abrirá en una nueva ventana)Report on structural studies of PfRH5 pathway components
9.5 TB activity of TBV candidates (se abrirá en una nueva ventana)Transmission Blocking activity of TBV candidates
5.4 Optimised process for biomanufacture of lead novel VLPs for GMP production (se abrirá en una nueva ventana)Optimised process for biomanufacture of lead novel VLPs for high yield larger scale GMP production
2.2 Ability of specific liver-stage antigen expression in hepatocytes to be detected by using marker epitopes (se abrirá en una nueva ventana)Report on the ability of specific liver-stage antigen expression in hepatocytes to be detected by using marker epitopes inserted into P. falciparum liver-stage antigens by CRISPR/Cas9 technology
4.4 Generate VLPs expressing Pfs25 alone, Pfs48/45 alone and bivalent VLPs (se abrirá en una nueva ventana)Generate VLPs expressing Pfs25 alone, Pfs48/45 alone and bivalent VLPs
8.5 Report on immuno-efficacy of blood-stage VLP/vaccine (se abrirá en una nueva ventana)Report on immunoefficacy of bloodstage VLPvaccine in clinical trial
1.2 Definition of 8 selected new candidate sporozoite antigens (se abrirá en una nueva ventana)Definition of 8 selected new candidate sporozoite antigens based on invasion analysis, proteomics and immunoepidemiology
9.4 Safety and Immunogenicity of TBV candidates (se abrirá en una nueva ventana)Safety and Immunogenicity of TBV candidates
7.8 Report on efficacy against sporozoite challenge of vectored prime-target immunisation combined with R21b in healthy volunteers (se abrirá en una nueva ventana)Report on efficacy against sporozoite challenge of vectored primetarget immunisation combined with R21b in healthy volunteers
5.5 feasibility of enhancing the durability of protective immune responses using VLPs in microcapsules (se abrirá en una nueva ventana)Report on the feasibility of enhancing the durability of protective immune responses using VLPs in microcapsules
Successful creation of project website
Publicaciones
Autores:
Roos M. de Jong, Susheel K. Singh, Karina Teelen, Marga van de Vegte-Bolmer, Geert-Jan van Gemert, Will J. R. Stone, Emily Locke, Jordan Plieskatt, Michael Theisen, Teun Bousema, Matthijs M. Jore
Publicado en:
Frontiers in Immunology, 2022, ISSN 1664-3224
Editor:
Frontiers Media SA
DOI:
10.3389/fimmu.2022.909060
Autores:
Surendra Kumar Kolli, Ahmed M. Salman, Jai Ramesar, Severine Chevalley-Maurel, Hans Kroeze, Fiona G. A. Geurten, Shinya Miyazaki, Ekta Mukhopadhyay, Catherin Marin-Mogollon, Blandine Franke-Fayard, Adrian V. S. Hill, Chris J. Janse
Publicado en:
PLOS ONE, Edición 16/7, 2021, Página(s) e0254498, ISSN 1932-6203
Editor:
Public Library of Science
DOI:
10.1371/journal.pone.0254498
Autores:
Susheel K. Singh1,2, Jordan Plieskatt3, Bishwanath K. Chourasia1,2, Vandana Singh1,2, Karin Lövgren Bengtsson4, Jenny M. Reimer 4, Renate C. van Daalen5, Karina Teelen5, Marga van de Vegte-Bolmer5, Geert-Jan van Gemert5, Matthijs M. Jore 5,6✉ and Michael Theisen
Publicado en:
NPJ Vaccines, 2021, ISSN 2059-0105
Editor:
Springer Nature
DOI:
10.1038/s41541-021-00383-8
Autores:
Ko KT, Lennartz F, Mekhaiel D, Guloglu B, Marini A, Deuker DJ, Long CA, Jore MM, Miura K, Biswas S, Higgins MK
Publicado en:
Nature Communications, 2022, ISSN 2041-1723
Editor:
Nature Publishing Group
DOI:
10.1038/s41467-022-33379-6
Autores:
Susheel K. Singh, Jordan Plieskatt, Bishwanath K. Chourasia, Amanda Fabra-García, Asier Garcia-Senosiain, Vandana Singh, Karin Lövgren Bengtsson, Jenny M. Reimer, Robert Sauerwein, Matthijs M. Jore, Michael Theisen
Publicado en:
Frontiers in Immunology, Edición 11, 2021, ISSN 1664-3224
Editor:
Frontiers in Immunology
DOI:
10.3389/fimmu.2020.606266
Autores:
Meerstein-Kessel L, Venhuizen J, Garza D, Proellochs NI, Vos EJ, Obiero JM, et al.
Publicado en:
PLoS Comput. Biol., 2021, ISSN 1553-7358
Editor:
PLOS
DOI:
10.1371/journal.pcbi.1008067
Autores:
Kirsten Dundas, Melanie J. Shears, Yi Sun, Christine S. Hopp, Cecile Crosnier, Tom Metcalf, Gareth Girling, Photini Sinnis, Oliver Billker, Gavin J. Wright
Publicado en:
Proceedings of the National Academy of Sciences, Edición 115/17, 2018, Página(s) 4477-4482, ISSN 0027-8424
Editor:
National Academy of Sciences
DOI:
10.1073/pnas.1719660115
Autores:
Daniel G.W. Alanine, Doris Quinkert, Rasika Kumarasingha, Shahid Mehmood, Francesca R. Donnellan, Nana K. Minkah, Bernadeta Dadonaite, Ababacar Diouf, Francis Galaway, Sarah E. Silk, Abhishek Jamwal, Jennifer M. Marshall, Kazutoyo Miura, Lander Foquet, Sean C. Elias, Geneviève M. Labbé, Alexander D. Douglas, Jing Jin, Ruth O. Payne, Joseph J. Illingworth, David J. Pattinson, David Pulido, Barnab
Publicado en:
Cell, Edición 178/1, 2019, Página(s) 216-228.e21, ISSN 0092-8674
Editor:
Cell Press
DOI:
10.1016/j.cell.2019.05.025
Autores:
Arianna Marini, Yu Zhou, Yuanyuan Li, Iona J. Taylor, Darren B. Leneghan, Jing Jin, Marija Zaric, David Mekhaiel, Carole A. Long, Kazutoyo Miura, Sumi Biswas
Publicado en:
Frontiers in Immunology, Edición 10, 2019, Página(s) Artiicle 2931, ISSN 1664-3224
Editor:
Unknown
DOI:
10.3389/fimmu.2019.02931
Autores:
Susheel K. Singh, Susan Thrane, Bishwanath K. Chourasia, Karina Teelen, Wouter Graumans, Rianne Stoter, Geert-Jan van Gemert, Marga G. van de Vegte-Bolmer, Morten A. Nielsen, Ali Salanti, Adam F. Sander, Robert W. Sauerwein, Matthijs M. Jore, Michael Theisen
Publicado en:
Frontiers in Immunology, Edición 10, 2019, Página(s) Article 1256, ISSN 1664-3224
Editor:
Unknown
DOI:
10.3389/fimmu.2019.01256
Autores:
Paulo Bettencourt
Publicado en:
Frontiers in Immunology, Edición 11, 2020, Página(s) Article 190, ISSN 1664-3224
Editor:
Unknown
DOI:
10.3389/fimmu.2020.00190
Autores:
Roos M. Jong, Surafel K. Tebeje, Lisette Meerstein‐Kessel, Fitsum G. Tadesse, Matthijs M. Jore, Will Stone, Teun Bousema
Publicado en:
Immunological Reviews, Edición 293/1, 2019, Página(s) 190-215, ISSN 0105-2896
Editor:
Blackwell Publishing Inc.
DOI:
10.1111/imr.12828
Autores:
Joseph J. Illingworth, Daniel G. Alanine, Rebecca Brown, Jennifer M. Marshall, Helen E. Bartlett, Sarah E. Silk, Geneviève M. Labbé, Doris Quinkert, Jee Sun Cho, Jason P. Wendler, David J. Pattinson, Lea Barfod, Alexander D. Douglas, Michael W. Shea, Katherine E. Wright, Simone C. de Cassan, Matthew K. Higgins, Simon J. Draper
Publicado en:
Frontiers in Immunology, Edición 10, 2019, Página(s) Article 1254, ISSN 1664-3224
Editor:
Unknown
DOI:
10.3389/fimmu.2019.01254
Autores:
Shinya Miyazaki, Annie S. P. Yang, Fiona J. A. Geurten, Catherin Marin-Mogollon, Yukiko Miyazaki, Takashi Imai, Surendra Kumar Kolli, Jai Ramesar, Severine Chevalley-Maurel, Ahmed M. Salman, Geert-Jan A. van Gemert, Youri M. van Waardenburg, Blandine Franke-Fayard, Adrian V. S. Hill, Robert W. Sauerwein, Chris J. Janse, Shahid M. Khan
Publicado en:
Frontiers in Cellular and Infection Microbiology, Edición 10, 2020, ISSN 2235-2988
Editor:
Frontiers Media S. A.
DOI:
10.3389/fcimb.2020.00270
Autores:
Boltryk SD, Passecker A, Alder A, Carrington E, van de Vegte-Bolmer M, van Gemert G-J, et al
Publicado en:
Nature Communications, 2021, ISSN 2041-1723
Editor:
Nature Publishing Group
DOI:
10.1038/s41467-021-24954-4
Autores:
Rameswara Reddy Segireddy, Kirsten Dundas, Julia Knoeckel, Francis Galaway, Laura Wood, Gavin J Wright, View ORCID ProfileAlexander D Douglas
Publicado en:
TBD, Edición TBD, 2020, Página(s) TBD
Editor:
TBD
DOI:
10.1101/2020.02.02.929190
Derechos de propiedad intelectual
Número de solicitud/publicación:
20
20058906
Fecha:
2020-03-30
Solicitante(s):
STATENS SERUM INSTITUT
Número de solicitud/publicación:
20
728129
Fecha:
2020-05-11
Solicitante(s):
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
Número de solicitud/publicación:
20
728129
Fecha:
2020-05-11
Solicitante(s):
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
Número de solicitud/publicación:
20
20058906
Fecha:
2020-03-30
Solicitante(s):
STATENS SERUM INSTITUT
Buscando datos de OpenAIRE...
Se ha producido un error en la búsqueda de datos de OpenAIRE
No hay resultados disponibles